Important Safety InformationPrescribing InformationReferencesRequest InfoReferral/Prescription Formfor patient

Support for your patients when an MS relapse rages on

When prescribing Acthar, there is an entire support team available through Mallinckrodt.

The Acthar support team includes the Acthar Sales Specialist, the Acthar Reimbursement Manager (ARM), and the Case Manager at the Acthar Hub, a no-cost resource for patients and healthcare professionals.

Sales Specialists

Acthar Sales Specialists provide clinical and promotional information, including tools and resources, to support Acthar treatment. They may provide contact information for other members of the Acthar support team 

ARMs

ARMs provide dedicated access and reimbursement support to help healthcare professionals work through the reimbursement process. ARMs can provide tools, resources, and patient status updates in person

Case Managers

Case Managers support patients and healthcare professionals from a central location, the Acthar Hub. Patient support includes helping patients through the reimbursement process, providing information about financial assistance options, scheduling injection training, and coordinating home delivery of Acthar with the Specialty Pharmacy. Support for healthcare professionals includes working with office staff to facilitate the insurance company approval process, as well as providing ongoing assistance for patients

The Acthar Hub helps make Acthar available to patients by:

Providing individualized Case Manager support to patients and healthcare professionals throughout the insurance approval process


Helping patients find appropriate financial assistance options, such as:

Co-pay assistance for eligible patients with commercial or private insurance

Acthar at no cost through the Acthar Patient Assistance Program for eligible uninsured, underinsured, or rendered uninsured patients with a valid, on-label prescription for Acthar*†

Information about Independent Charitable Foundation (ICF) funds for government-insured patients with a valid, on-label prescription for Acthar


Offering in-home, online, and phone injection training by licensed nurses at no cost


Coordinating home delivery of Acthar with the Specialty Pharmacy


*Acthar Patient Assistance Program patient eligibility criteria:

Program administered via a third-party organization. 

Getting started is simple

1

Complete the Acthar Start Form and fax it to the Acthar Hub at
1-877-937-2284.

2

The Acthar Hub faxes back a confirmation and contacts the office within 4 business hours to explain next steps, including prior authorization requirements.

3

The Acthar Hub may contact the office staff with questions. Responding in a timely manner helps ensure patients get Acthar as soon as possible.

If you have any questions, contact the Acthar Hub
The Case Manager at the Acthar Hub will keep office staff and patients informed about the status of their Acthar prescription.

Patients with commercial or private insurance may be eligible for $0 co-pays

Upon successful enrollment, eligible patients with commercial or private insurance—who are not covered by government insurance—will receive the following:

Inform patients about the Acthar Commercial Co-pay Program. Let them know they can expect a call from their Hub Case Manager to discuss program eligibility. (See Terms and Conditions.)

Patients who do not qualify for this program may call the Hub toll-free at 1-888-435-2284 and speak to their Case Manager to learn if other assistance options may be available.

Terms and Conditions:

  • The Acthar Commercial Co-pay Program provides drug co-pay assistance of up to $25,000 per calendar year for each eligible patient
  • This program is valid for eligible privately and commercially insured patients. Uninsured patients are not eligible for this program
  • This program is not valid for prescriptions for which payment may be made in whole or in part under federal or state health programs, including, but not limited to, Medicare or Medicaid, or where prohibited by law
  • Patient must have a valid Acthar prescription for an FDA-approved, on-label indication
  • Patient must be a permanent US resident. This program is not valid outside of the United States
  • Patient (or patient’s legal representative) must be 18 years of age or older to opt in to program
  • This program offer is limited to 1 membership per person and is not transferable
  • Patients should consult their insurance provider concerning any limitations that may apply to this program under their insurance policy
  • This program does not constitute prescription drug coverage or insurance and is not intended to substitute for such coverage
  • Patients are responsible for any co-payment or coinsurance costs above and beyond the program’s annual maximum benefit
  • Absent a change in Massachusetts law, effective July 1, 2019, the Acthar Commercial Co-pay Program will no longer be valid for residents of Massachusetts
  • Mallinckrodt ARD, Inc. reserves the right to terminate or modify this program at any time without notice

Indication

H.P. Acthar® Gel (repository corticotropin injection) is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease.

View Full

Important Safety Information

Contraindications
  • Acthar should never be administered intravenously.
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar.
  • Acthar is contraindicated where congenital infections are suspected in infants.
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins.

Indication

H.P. Acthar® Gel (repository corticotropin injection) is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease.

Warnings and Precautions
  • The adverse effects of Acthar are related primarily to its steroidogenic effects.
  • Acthar may increase susceptibility to new infection or reactivation of latent infections.
  • Suppression of the hypothalamic-pituitary-axis (HPA) may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment.
  • Cushing’s syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms.
  • Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium and potassium levels may need to be monitored.
  • Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy.
  • Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding.
  • Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression, and psychosis. Existing conditions may be aggravated.
  • Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis.
  • Prolonged use of Acthar may produce cataracts, glaucoma and secondary ocular infections. Monitor for signs and symptoms.
  • Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity.
  • There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver.
  • Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients.
  • Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy.
  • Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Adverse Reactions
  • Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain.
  • Specific adverse reactions reported in IS clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve.

Other adverse events reported are included in the full Prescribing Information.

Please see full Prescribing Information.

Indication

H.P. Acthar® Gel (repository corticotropin injection) is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease.

View Full

Important Safety Information

Contraindications
  • Acthar should never be administered intravenously.
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar.
  • Acthar is contraindicated where congenital infections are suspected in infants.
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins.

Indication

H.P. Acthar® Gel (repository corticotropin injection) is indicated for the treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease.

Warnings and Precautions
  • The adverse effects of Acthar are related primarily to its steroidogenic effects.
  • Acthar may increase susceptibility to new infection or reactivation of latent infections.
  • Suppression of the hypothalamic-pituitary-axis (HPA) may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment.
  • Cushing’s syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms.
  • Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium and potassium levels may need to be monitored.
  • Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy.
  • Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding.
  • Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression, and psychosis. Existing conditions may be aggravated.
  • Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis.
  • Prolonged use of Acthar may produce cataracts, glaucoma and secondary ocular infections. Monitor for signs and symptoms.
  • Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity.
  • There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver.
  • Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients.
  • Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy.
  • Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Adverse Reactions
  • Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain.
  • Specific adverse reactions reported in IS clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve.

Other adverse events reported are included in the full Prescribing Information.

Please see full Prescribing Information.

Are you a US healthcare professional?

The information in the following section is intended for US healthcare professionals only.